Therapies for benign prostatic hyperplasia
Concato, J.; Horwitz, R.I.; Feinstein, A.R.; Elmore, J.G.; Schiff, S.F.
JAMA 269(7): 867
1993
ISSN/ISBN: 0098-7484 PMID: 7678874 Document Number: 418648
Document emailed within 1 workday
Related Documents
Jonas, U.; Melchior, H.; Rübben, H. 1998: Recommendations for billing alternative therapy of benign prostatic hyperplasia. Laser therapy of benign prostatic hyperplasia Der Urologe. Ausg. a 37(1): 110-111Bogdanowicz, J.F.; Bentvelsen, F.M.; Oosterom, R.; Schroeder, F.H. 1991: Evaluation of prostate-specific antigen and prostatic acid phosphatase in untreated prostatic carcinoma and benign prostatic hyperplasia Scandinavian Journal of Urology and Nephrology. Supplementum 138: 97-103
Brannen, G.E.; Coffey, D.S. 1977: Tumor-specific immunity in patients with prostatic adenocarcinoma or benign prostatic hyperplasia Cancer Treatment Reports 61(2): 211-216
Kletscher, B.A.; Oesterling, J.E. 1995: Prostatic stents. Current perspectives for the management of benign prostatic hyperplasia Urologic Clinics of North America 22(2): 423-430
Gu, F. 2000: Epidemiological survey of benign prostatic hyperplasia and prostatic cancer in China Chinese Medical Journal 113(4): 299-302
Abdul-Muhsin, H.M.; Jakob, N.J.; McLemore, R.M.; McAdams, S.B.; Humphreys, M.R. 2016: Infectious complications associated with the use of temporary prostatic urethral stents in patients with benign prostatic hyperplasia Canadian Journal of Urology 23(5): 8465-8470
Pretlow, T.G.; Whitehurst, G.B.; Pretlow, T.P.; Hunt, R.S.; Jacobs, J.M.; McKenzie, D.R.; McDaniel, H.G.; Hall, L.M.; Bradley, E.L. 1982: Decrease in creatine kinase in human prostatic carcinoma compared to benign prostatic hyperplasia Cancer Research 42(11): 4842-4848
Blanc, M.; Sacrini, A.; Avogadro, A.; Gattamorta, M.; Lazzerini, F.; Gattoni, F.; Cretti, F. 1998: Prostatic volume: suprapubic versus transrectal ultrasonography in the control of benign prostatic hyperplasia La Radiologia Medica 95(3): 182-187
Granados Loarca, E.A. 1999: Medical treatment of benign prostatic hyperplasia. The efficacy of finasteride depends on prostatic volume Archivos Espanoles de Urologia 52(3): 201-208
Maygarden, S.J.; Strom, S.; Ware, J.L. 1992: Localization of epidermal growth factor receptor by immunohistochemical methods in human prostatic carcinoma, prostatic intraepithelial neoplasia, and benign hyperplasia Archives of Pathology and Laboratory Medicine 116(3): 269-273
Schönberger, B. 1986: Benign prostatic hyperplasia Zentralblatt für Chirurgie 111(10): 569-588
Hiraoka, Y.; Sa, I. 2002: Biochemical diagnosis of benign prostatic hyperplasia (including differential diagnosis with prostatic carcinoma) Nihon Rinsho. Japanese Journal of Clinical Medicine 60(Suppl 11): 342-345
Neal, D.E.; Hegarty, P. 2003: Key questions in benign prostatic hyperplasia Practitioner 247(1652): 886-889
Garnett, S.; Abrams, P. 2001: Managing benign prostatic hyperplasia Practitioner 245(1627): 830
Tan, E.C. 1995: Pharmacotherapy in benign prostatic hyperplasia Annals of the Academy of Medicine Singapore 24(4): 615-618
Thomas, D. 1997: When to investigate benign prostatic hyperplasia Practitioner 241(1576): 408-413
Rodríguez, J.V. 2001: Prostatotomy in benign prostatic hyperplasia. Why? Archivos Espanoles de Urologia 54(7): 667-673
Carlin, B.I.; Resnick, M.L. 1996: Assessment of the patient with benign prostatic hyperplasia Comprehensive Therapy 22(9): 586-591
McConnell, J.D. 1995: Benign prostatic hyperplasia. Hormonal treatment Urologic Clinics of North America 22(2): 387-400
Ekman, P. 1992: Drug therapy of benign prostatic hyperplasia Lakartidningen 89(45): 3803-3804